September 30, 2015Open Access
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Key Points
Key points are not available for this paper at this time.
Abstract
Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis. (Funded by Amgen; AMAGINE-2 and AMAGINE-3 ClinicalTrials.gov numbers, NCT01708603 and NCT01708629.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Mark Lebwohl
University of Hawaiʻi at Mānoa
B
Bruce Strober
Yale University
A
Alan Menter
University of Rome Tor Vergata
Journals
New England Journal of Medicine
Actions
Institutions
Harvard University
University of California, San Francisco
Massachusetts General Hospital
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...